10:37 AM EST - Eupraxia Pharmaceuticals Inc. : Announced positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading up $0.34 at $6.07.
